Key result
USPIO-enhanced MRI shows no benefit over LGE and T2 mapping in acute myocarditis.
Why the study?
Does USPIO-enhanced MRI improve the diagnosis of acute myocarditis compared to standard LGE and T2 mapping MRI in patients with suspected acute myocarditis?
Does USPIO-enhanced MRI improve the diagnosis of acute myocarditis compared to standard LGE and T2 mapping MRI in patients with suspected acute myocarditis?
p-value: p=>0.05
USPIO-enhanced MRI with ferumoxytol does not add clinically relevant diagnostic information over standard LGE and T2 mapping in acute myocarditis.
USPIO-enhanced MRI adds no diagnostic value over LGE and T2 mapping in acute myocarditis; hypothesis-generating and should not yet change practice.
OBJECTIVES: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI can detect tissue-resident macrophage activity and identify cellular inflammation within tissues. We hypothesised that USPIO-enhanced MRI would provide a non-invasive imaging technique that would improve the diagnosis and management of patients with acute myocarditis. METHODS: Ten volunteers and 14 patients with suspected acute myocarditis underwent T2, T2* and late gadolinium enhancement (LGE) 3T MRI, with further T2* imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) infusion, at baseline and 3 months. Myocardial oedema and USPIO enhancement were determined within areas of LGE as well as throughout the myocardium. RESULTS: , p>0.05). Imaging after 3 months in patients with myocarditis revealed a reduction in volume of LGE, a reduction in oedema measures within regions displaying LGE and improvement in ejection fraction (mean -19.7 mL, 95% CI (-0.5 to -40.0)), -5.8 ms (-0.9 to -10.7) and +6% (0.5% to 11.5%), respectively, p<0.05 for all). CONCLUSION: In patients with acute myocarditis, USPIO-enhanced MRI does not provide additional clinically relevant information to LGE and T2 mapping MRI. This suggests that tissue-resident macrophages do not provide a substantial contribution to the myocardial inflammation in this condition.Clinical trial registration NCT02319278; Results.
No takes yet. Share an insight, caveat, or question.
Stirrat et al. (2017) studied Acute myocarditis (n=24). USPIO-enhanced MRI (ferumoxytol) vs. LGE and T2 mapping MRI was evaluated on Myocardial oedema and USPIO enhancement within areas of LGE and throughout the myocardium (p=>0.05). USPIO-enhanced MRI using ferumoxytol did not provide additional clinically relevant information to LGE and T2 mapping MRI in patients with acute myocarditis (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: